PWC
VKTX icon

PYA Waltman Capital’s Viking Therapeutics VKTX Stock Holding History

PYA Waltman Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$3K – 187
2022
Q3 		$3K Hold
1,000
– – ﹤0.01% 172
2022
Q2 		$3K Hold
1,000
– – ﹤0.01% 181
2022
Q1 		$3K Hold
1,000
– – ﹤0.01% 178
2021
Q4 		$5K Buy
+1,000
New +$5.61K ﹤0.01% 164

Other funds holding VKTX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PYA Waltman Capital's VKTX Position: Q4 2022 in Review

PYA Waltman Capital sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 1,000 shares — an estimated $3K sold.

PYA Waltman Capital first reported a position in VKTX in Q4 2021 and held it in 4 quarters. The position peaked at $5K in Q4 2021. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • PYA Waltman Capital reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PYA Waltman Capital sold 1,000 Viking Therapeutics shares in Q4 2022, an estimated $3K.
  • PYA Waltman Capital first reported a position in Viking Therapeutics in Q4 2021 and held it in 4 quarters.
  • PYA Waltman Capital's Viking Therapeutics position peaked at $5K in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on PYA Waltman Capital's 13F filing for Q4 2022, filed 14 Feb 2023.